High-doses epoetin alpha in patients with multiple myeloma-related anaemia: Early response and effective maintenance treatment with a longer dosing interval

HAEMA

Volumn 6, Issue 2, 2003, Pages 187-192

  Niscola, Pasquale ^a,b   Scaramucci, Laura ^a   Menichelli, Luigi ^a   Bongarzoni, Velia ^a   De Gregoris, Cinzia ^a   Morucci, Marco ^a   Tini, Vincenzo ^a   Montanaro, Marco ^a  

^a Montefiascone Hospital   (Italy)

^b Ospedale di Montefiascone   (Italy)

Author keywords

Anemia; Epoetin alpha; Erythropoietin; Multiple myeloma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; INTERFERON; IRON; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; MAINTENANCE THERAPY; MALE; MULTIPLE MYELOMA; TITRIMETRY;

EID: 0038512410     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Beguin Y, Yerna M, Loo M et al. Erythropoiesis in multiple myeloma: Defective red cell production due to inappropriate erythropoietin production. Br J Haematol 1992; 82: 648.
2. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-1994.
3. Allen A, Breen C, Yaqoob MM et al. Inhibition of CFUE colony formation in uremic patients with inflammatory disease: role of the IFN-gamma and TNF-alpha. J Invest Med 1999; 47: 204-211.
4. Koury MJ. The anemia of chronic disease: TNF-alpha involvement in erythroid apoptosis. Blood 2002; 100: 373-374.
5. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron and erythropoiesis. Blood 2000; 96: 823-833.
6. Silvestris F, Tucci M, Cafforio P et al. Fas-L up regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 2001; 97: 1155-1164.
7. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 332: 1693-1699.
8. Cazzola M, Ponchio L, Beguin Y et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992, 79: 29-37.
9. Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and nonHodgkin's lymphoma. A randomized multicenter study. Blood 1996; 87: 2675-2683.
10. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood 1997; 89: 4248-4267.
11. Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-2320.
12. Ludwig H, Rai K, Blade J et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia:epoetin treatment recommendations. Hematol J 2002; 3: 121-130.
13. Siakantaris MP, Angelopoulou MK, Vassilakopoulos TP et al. Restoration of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin. Maintenance is necessary to sustain response. Leuk Lymphoma 2000; 40: 141-147.
14. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
15. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842.
16. Crémieux PY, Barret B, Anderson K, Slavin MB. Cost of Outpatient Blood Transfusion in Cancer Patients. J Clin Oncol 2000; 14: 2755-2761.
17. Crémieux PY, Finkelstein SN, Berndt ER, Crawford JK, Slavin MB. Cost Effectiveness, Quality-Adjusted Life-years and Supportive Care. Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia. Pharmacoeconomics 1999; 16: 459-472.
18. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113: 172-179.
19. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non Hodgkin's lymphoma: dose findings and identification of predictors of response. Blood 1995; 86: 4446-4453.
20. Adamson JW, Ludwig H. Predicting the hematopoietic, response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Oncology 1999; 56: 46-53.
21. Kasper C. Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies. Ann Hematol 2001; 80: 319-329.
22. Yves Beguin. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002; 87: 1209-1221.
23. Glaspy J, Cavill I. Role of the Iron in optimizing Responses of anemic Cancer Patients to Erythropoietin. Oncology 1999; 13: 461-483.
24. Olijhoek G, Megens JG, Musto P et al. Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001; 41: 957-963.
25. Straus DJ. Epoetin alfa as a supportive measure in hematologic malignancies. Semin Hematol 2002; 39(suppl. 3): 25-31.
26. Stasi R, Brunetti M, Terzoli E et al. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 2002; 99: 1578-1584.
27. Cerami A, Brines ML, Ghezzi P et al. Effects of epoetin alfa on the central nervous system. Semin Oncol 2001; 28(2 Suppl 8): 66-70.
28. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
29. Mittelman M, Neumann D, Peled A et al. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci U.S.A. 2001; 98: 5181-5186.